San Francisco-based AI pharmaceutical company ReviR Therapeutics has raised around USD 20 million in a pre-Series A funding round led by 5Y Capital (formerly Morningside Venture Capital) and CDH Investments. Other investors also participated in the round, including Shunwei Capital and Sky9 Capital.
The proceeds will be directed toward further developing its AI drug discovery platform VoyageR and expanding its research team (currently employing around 25 wet/dry lab scientists).
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.